-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Maintains Outperform on Arcus Biosciences, Raises Price Target to $49

Benzinga·03/02/2026 20:23:51
Listen to the news
Leerink Partners analyst Geoffrey Porges maintains Arcus Biosciences (NYSE:RCUS) with a Outperform and raises the price target from $36 to $49.